Pembrolizumab–chemotherapy for advanced oesophageal cancer

Ziv Gil; Salem Billan

doi:10.1016/S0140-6736(21)01607-X

Pembrolizumab–chemotherapy for advanced oesophageal cancer

Ziv Gil
, Salem Billan

Research output: Contribution to journal › Comment/debate

6 Scopus citations

Original language	English
Pages (from-to)	726-727
Number of pages	2
Journal	The Lancet
Volume	398
Issue number	10302
DOIs	https://doi.org/10.1016/S0140-6736(21)01607-X
State	Published - 28 Aug 2021
Externally published	Yes

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0140-6736(21)01607-X

Cite this

@article{19093053d5eb40189a1fc6d0531bc5ed,

title = "Pembrolizumab–chemotherapy for advanced oesophageal cancer",

author = "Ziv Gil and Salem Billan",

year = "2021",

month = aug,

day = "28",

doi = "10.1016/S0140-6736(21)01607-X",

language = "English",

volume = "398",

pages = "726--727",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "10302",

}

TY - JOUR

T1 - Pembrolizumab–chemotherapy for advanced oesophageal cancer

AU - Gil, Ziv

AU - Billan, Salem

PY - 2021/8/28

Y1 - 2021/8/28

UR - https://www.scopus.com/pages/publications/85113577510

U2 - 10.1016/S0140-6736(21)01607-X

DO - 10.1016/S0140-6736(21)01607-X

M3 - Comment/debate

C2 - 34454657

AN - SCOPUS:85113577510

SN - 0140-6736

VL - 398

SP - 726

EP - 727

JO - The Lancet

JF - The Lancet

IS - 10302

ER -

Pembrolizumab–chemotherapy for advanced oesophageal cancer

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this